Table 3.
Randomized controlled trials comparing different durations of dual antiplatelet therapy. ASA, aspirin; BARC, Bleeding Academic Research Consortium; Mos, months; TIMI, Thrombolysis in Myocardial Infarction; ∨, statistically significant reduction in outcome in experimental group compared to control group; ∧, statistically significant increase in outcome in experimental group compared to control group; =, no statistical difference in outcome between the two groups.
| Trial | N | Experimental Group | Mos | Control Group | Mos | Ischemic Outcome | Results | Bleeding Outcome | Results |
|---|---|---|---|---|---|---|---|---|---|
| CURE [3] | 12,562 | ASA + Clopidogrel | 3–12 | ASA + Placebo | 3–12 | Death from cardiovascular causes, non-fatal myocardial infarction, or stroke | ∨ | TIMI | ∧ |
| PLATO [9] | 18,624 | ASA + Ticagrelor | 3–12 | ASA + Clopidogrel | 3–12 | Death from vascular causes, myocardial infarction, or stroke | ∨ | TIMI | = |
| TRITON [8] | 13,608 | ASA + Prasugrel | 6–15 | ASA + Clopidogrel | 6–15 | Death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke | ∨ | TIMI | = |
| TWILIGHT [60] | 7119 | Ticagrelor + ASA Ticagrelor + Placebo |
3 9 |
Ticagrelor + ASA | 12 | Death from any cause, non-fatal myocardial infarction, or non-fatal stroke | = | BARC 2, 3, 5 | ∨ |
| GLOBAL LEADERS [61] | 15,991 | Ticagrelor + ASA Ticagrelor | 1 23 |
Ticagrelor/Clopidogrel + ASA ASA |
12 12 |
All-cause mortality or non-fatal myocardial infarction | = | BARC 3, 5 | ∨ |
| TICO [62] | 3056 | Ticagrelor + ASA Ticagrelor |
3 9 |
Ticagrelor + ASA | 12 | Death, myocardial infarction, stent thrombosis, stroke, and target vessel revascularization | = | TIMI | ∨ |